Synthetic route eliminates need for high potency equipment during manufacture of proprietary drug candidates Fort Collins, CO, February 25, 2025...

Provost & Chief Academic Officer of Howard University brings scientific experience and new perspectives on the consequences of sickle cell...

Adds extensive life science senior experience and transactional capability to the Board of Directors Fort Collins, CO, July 1, 2020...

Drug candidate active against EGFR and KRAS mutant lung cancer cell lines Fort Collins, CO, June xx, 2020 – Cetya...

Novel Chemistry Allows Conjugation of Largazole Analogs to Receptor Ligands or Other Cytotoxic Agents Fort Collins, CO, January 21, 2020...

 $1,000,000 NIH Grant will further development of Cetya’s HDAC inhibitor CT-101 for treatment of sickle cell disease   Fort Collins, CO,...

$170,000 Colorado Grant will advance Cetya’s novel targeted HDAC inhibitor program.

$240,000 Grant will allow evaluation of Cetya’s HDAC inhibitors for treatment of sickle cell disease.

$220,000 Round includes Canadian firm InSynchrony Ventures Inc Proceeds will advance oncology drug development. Fort Collins, CO, May 8, 2017...